Drug intelligence / Profile preview

SL-28

Development stage: Phase 2
Lead developer: Second Life Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

SL-28 is a cell-based therapy developed by Second Life Therapeutics, intended for the treatment of advanced solid tumors. It consists of allogeneic, non-HLA matched leukocytes isolated from healthy donors, which are activated through a proprietary process. These cells are stored at -80°C until use and are administered intravenously. Researchers believe SL-28 will be effective due to its direct activity against various tumor types.

Beyond the preview

Go deeper on SL-28.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SL-28.

Explore the full profile